AI assistant
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2024
Feb 13, 2024
32254_dirs_2024-02-13_89dce62a-0e09-4d99-9e45-38b9b166a1dc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2024-02-09
Reporting Person: Lurker Nancy (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-09 | Common Stock | M | 20000.00 | $0.00 | Acquired | 155441.00 | Direct |
| 2024-02-09 | Common Stock | M | 17534.00 | $0.00 | Acquired | 172975.00 | Direct |
| 2024-02-09 | Common Stock | F | 7962.00 | $28.80 | Disposed | 165013.00 | Direct |
| 2024-02-09 | Common Stock | F | 6981.00 | $28.80 | Disposed | 158032.00 | Direct |
| 2024-02-13 | Common Stock | G | 74681.00 | $0.00 | Disposed | 83351.00 | Direct |
| 2024-02-13 | Common Stock | G | 74681.00 | $0.00 | Acquired | 126889.00 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-09 | Restricted Stock Units | $0.00 | M | 17534.00 | Disposed | 2031-02-09 | Common Stock (17534.00) | Direct |
| 2024-02-09 | Restricted Stock Units | $0.00 | M | 20000.00 | Disposed | 2032-02-09 | Common Stock (20000.00) | Direct |
| 2024-02-13 | Stock Option (Right to Buy) | $12.90 | G | 3116.00 | Disposed | 2030-02-28 | Common Stock (3116.00) | Direct |
| 2024-02-13 | Stock Option (Right to Buy) | $12.90 | G | 3116.00 | Acquired | 2030-02-28 | Common Stock (3116.00) | Indirect |
| 2024-02-13 | Stock Option (Right to Buy) | $13.13 | G | 4452.00 | Disposed | 2031-02-09 | Common Stock (4452.00) | Direct |
| 2024-02-13 | Stock Option (Right to Buy) | $13.13 | G | 4452.00 | Acquired | 2031-02-09 | Common Stock (4452.00) | Indirect |
| 2024-02-13 | Stock Option (Right to Buy) | $10.13 | G | 5000.00 | Disposed | 2032-02-09 | Common Stock (5000.00) | Direct |
| 2024-02-13 | Stock Option (Right to Buy) | $10.13 | G | 5000.00 | Acquired | 2032-02-09 | Common Stock (5000.00) | Indirect |
Footnotes
F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2: On February 13, 2024, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust.
F3: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.
F5: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
F6: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust").
F7: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 28, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.
F8: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.
F9: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.